Research Topics
| Andre GoySummaryAffiliation: Hackensack University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Mantle cell lymphoma: evolving novel optionsAndre Goy
Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA
Curr Oncol Rep 9:391-8. 2007..Other small molecules have shown encouraging activity, including mTOR and Bcl-2 inhibitors, novel antibodies, and new cytotoxic agents. Future trials will also benefit from new molecular approaches through pharmacogenomics...
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyA Goy
The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
Ann Oncol 20:520-5. 2009..We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL)...- The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphomaAndre Goy
Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 108:10-20. 2006..The results support the feasibility of FNA-based transcription profiles in patients with FL or LBCL, which, in combination with morphology and immunophenotyping, can help in the subtyping of these entities... - Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trialAndre Goy
The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA
Leuk Lymphoma 51:1269-77. 2010..These biomarkers data begin to illuminate bortezomib's mechanism of action in lymphoma... - Mantle cell lymphoma: the promise of new treatment optionsAndre Goy
Lymphoma Division, John Theurer Cancer Center, Hackensack Medical University Cancer, NJ Center, Hackensack, 07601, USA
Crit Rev Oncol Hematol 80:69-86. 2011..g. bortezomib-R-chemo) to post-induction strategies such as consolidation (e.g. radioimmunotherapy, bortezomib) or maintenance therapy (e.g. rituximab, lenalidomide)... - Expanding therapeutic options in mantle cell lymphomaAndre Goy
Lymphoma Division, Hackensack University Medical Center, NJ 07601, USA
Clin Lymphoma Myeloma 7:S184-91. 2007.... - New directions in the treatment of mantle cell lymphoma: an overviewAndre Goy
Hackensack University Medical Center, Hackensack, NJ 07601, USA
Clin Lymphoma Myeloma 7:S24-32. 2006..A molecular approach to define biomarkers might help identify subgroups of patients and help develop rational therapies... - Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Br J Haematol 150:200-8. 2010..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL... - High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera
Department of Lymphoma, Unit 429, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 23:7013-23. 2005..To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL)... - Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd 429, Houston, TX 77030, USA
Br J Haematol 151:47-53. 2010..In particular, there was no pulmonary or neurological dose-limiting toxicity, showing that bortezomib can be safely combined with R-HyperCVAD and R-M/A... - Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 459, Houston, TX 77030, USA
J Clin Oncol 23:667-75. 2005..Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma... 
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes
Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 119:4123-8. 2012..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...- Establishment and characterization of a new mantle cell lymphoma cell line M-1Andre Goy
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Leuk Lymphoma 45:1255-60. 2004..The characterization of a new mantle cell lymphoma cell line is a unique tool for studying the biology of this subtype of lymphoma for which only a few cell lines have been established... - Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaYasuhiro Oki
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 112:831-6. 2008..The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL... - Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphomaBarbara Pro
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Lymphoma 47:481-5. 2006..In these previously treated patients with NHL, a single dose of pegfilgrastim was effective in promoting neutrophil count recovery after paclitaxel and topotecan, and allowed patients to receive the next planned dose on time... - Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphomaNam H Dang
The University of Texas M D Anderson Cancer Center, Department of Lymphoma Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
J Clin Oncol 22:4095-102. 2004..A phase II study was performed to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NHL... - Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphomaAnas Younes
Department of Lymphoma and Myeloma, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Eur J Cancer 42:2976-81. 2006..Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule... - Update on the proteasome inhibitor bortezomib in hematologic malignanciesAndre Goy
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Lymphoma 4:230-7. 2004..Bortezomib represents an excellent example of how progress in understanding the biology of cancer cells can impact clinical practice and lead toward a new era of rational therapeutics... - Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVADAnthony R Mato
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
Cancer 118:3565-70. 2012.... - Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocationsAndre Goy
Departments of Lymphoma, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
Lab Invest 83:913-6. 2003 - Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideAnthony R Mato
Lymphoma Division, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, USA
Oncologist 17:694-707. 2012..The results of these studies will help our understanding about how to best integrate proteasome inhibition in the management of NHL and continue to improve patient outcomes... - A pilot study of rituximab in patients with recurrent, classic Hodgkin diseaseAnas Younes
Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:310-4. 2003..Rituximab is used to primarily deplete normal B cells from HD lesions... - Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang
MD Anderson Cancer Center, Houston, TX 77030, USA
Oncol Rep 10:1513-8. 2003..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications... - Bortezomib in mantle cell lymphomaK Stephen Suh
Jurist Research Center, 30 Prospect Avenue, Hackensack NJ 07601, USA
Future Oncol 4:149-68. 2008..An obvious effort is needed to enroll patients on clinical trials, the design of which might benefit from pharmacogenomics and a better understanding of MCL biology and its diversity... - Ovarian cancer biomarkers for molecular biosensors and translational medicineK Stephen Suh
Tissue Bank and Cancer Research Program, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA
Expert Rev Mol Diagn 10:1069-83. 2010..The article also presents a global view of all known potential biomarkers and mutations for ovarian cancer from NCI's Cancer Gene Index developed by Sophic, and Sanger's Catalogue of Somatic Mutations in Cancer database... - Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphomaGeorge Z Rassidakis
Department of Lymphoma-Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:2213-20. 2003..Future studies should explore the underlying molecular mechanisms of MUC-1 expression in these tumors and its role as a target for novel therapeutic strategies... - Survivin expression predicts poorer prognosis in anaplastic large-cell lymphomaEllen J Schlette
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 22:1682-8. 2004..Modulation of survivin expression or function may provide a novel target for experimental therapy in patients with ALCL... - Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaJorge E Romaguera
Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 97:586-91. 2003..The impact of endoscopic assessment on the management of MCL patients is unknown... - Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang
Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Br J Haematol 138:502-5. 2007..The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular lymphoma, and 100% in the three patients with rituximab-sensitive tumour. Most toxicities were low grade and transient, and myelotoxicity was uncommon... - Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issuesDaniel H Silverman
Department of Nuclear Medicine, UCLA Medical Center, Los Angeles, CA, USA
Cancer Treat Rev 30:165-72. 2004..Therefore, in this review, we attempt to compare the relative merits of (Bexxar and Zevalin) and address important practical considerations that may influence patient and physician choices regarding treatment using these agents... - Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?John Gerecitano
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 134:391-8. 2006..In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients... - Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphomaNam H Dang
Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Br J Haematol 136:439-47. 2007..Further studies of denileukin diftitox in combination with other agents are warranted in previously untreated and relapsed/refractory T-NHL... - MUC-1 mucin protein expression in B-cell lymphomasJulie Teruya-Feldstein
Department of Pathology, Cell Biology and Immunology Programs, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Appl Immunohistochem Mol Morphol 11:28-32. 2003..For all cases, MUC-1 mucin expression correlated with a previous history of lymphoma (p=0.003)... - Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphomaEunice S Wang
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6306, USA
Cancer 98:1196-205. 2003..In the post-HAART era, intensive chemotherapy such as CODOX-M/IVAC may be appropriate in all adult patients with BL, and especially those with poor prognostic factors, regardless of HIV status...